The invention relates to the technical field of traditional Chinese medicine, and discloses a method of traditional Chinese medicine and microcapsule preparation suitable for nasopharyngeal cancer tumor inhibitors. A traditional Chinese medicine suitable for nasopharyngeal cancer tumor inhibitors, including: Hedyotis Diffusa, Scutellaria Barbata, Arrowshaped Tinospora Root, Rehmanniae Radix Preparata, Radix Curcumae, Crotonis Fructus, Leonurus Artemisia, Ramulus Cinnamomi, Forsythiae Fructus, Taraxacum, Radix Platycodonis and White Vinegar. Among them, the raw materials for the weight ratio are as follows: 60 grams of Hedyotis Diffusa, 30 grams of Scutellaria Barbata, 9-12 grams of Arrowshaped Tinospora Root, 18 grams of Rehmanniae Radix Preparata, 19 grams of Radix Curcumae, 7.5 grams of Crotonis Fructus, 10 grams of Leonurus Artemisia, 7-10 grams of Ramulus Cinnamomi, 10 grams of Forsythiae Fructus, 15-30 grams of Taraxacum, 10 g of Radix Platycodonis, and 30 ml of White Vinegar.

The invention relates to the technical field of traditional Chinese medicine, and discloses a method of traditional Chinese medicine and microcapsule preparation suitable for nasopharyngeal cancer tumor inhibitors. A traditional Chinese medicine suitable for nasopharyngeal cancer tumor inhibitors, including: Hedyotis Diffusa, Scutellaria Barbata, Arrowshaped Tinospora Root, Rehmanniae Radix Preparata, Radix Curcumae, Crotonis Fructus, Leonurus Artemisia, Ramulus Cinnamomi, Forsythiae Fructus, Taraxacum, Radix Platycodonis and White Vinegar. Among them, the raw materials for the weight ratio are as follows: 60 grams of Hedyotis Diffusa, 30 grams of Scutellaria Barbata, 9-12 grams of Arrowshaped Tinospora Root, 18 grams of Rehmanniae Radix Preparata, 19 grams of Radix Curcumae, 7.5 grams of Crotonis Fructus, 10 grams of Leonurus Artemisia, 7-10 grams of Ramulus Cinnamomi, 10 grams of Forsythiae Fructus, 15-30 grams of Taraxacum, 10 g of Radix Platycodonis, and 30 ml of White Vinegar.

The invention relates to the technical field of traditional Chinese medicine, and discloses a method of traditional Chinese medicine and microcapsule preparation suitable for nasopharyngeal cancer tumor inhibitors. A traditional Chinese medicine suitable for nasopharyngeal cancer tumor inhibitors, including: Hedyotis Diffusa, Scutellaria Barbata, Arrowshaped Tinospora Root, Rehmanniae Radix Preparata, Radix Curcumae, Crotonis Fructus, Leonurus Artemisia, Ramulus Cinnamomi, Forsythiae Fructus, Taraxacum, Radix Platycodonis and White Vinegar. Among them, the raw materials for the weight ratio are as follows: 60 grams of Hedyotis Diffusa, 30 grams of Scutellaria Barbata, 9-12 grams of Arrowshaped Tinospora Root, 18 grams of Rehmanniae Radix Preparata, 19 grams of Radix Curcumae, 7.5 grams of Crotonis Fructus, 10 grams of Leonurus Artemisia, 7-10 grams of Ramulus Cinnamomi, 10 grams of Forsythiae Fructus, 15-30 grams of Taraxacum, 10 g of Radix Platycodonis, and 30 ml of White Vinegar.

The invention discloses an application of phlegmyheatclear in preparation of a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease. The present invention studies the effect of phlegmyheatclear on model of rats with acute exacerbation of chronic obstructive pulmonary disease. Results show that high dose, middle dose, or low dose of phlegmyheatclear can, during the acute exacerbation of chronic obstructive pulmonary disease, improve the lung function of the rats and the pathological damage of lung tissues of the rats in different degrees, and it is dose dependent. High dose, middle dose, or low dose of phlegmyheatclear can improve inflammatory reaction in different degrees. For the drug effects, the high dose and the middle dose of phlegmyheatclear are better than the low dose of phlegmyheatclear. Therefore, phlegmyheatclear can be used to prepare a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease.

The invention discloses an application of phlegmyheatclear in preparation of a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease. The present invention studies the effect of phlegmyheatclear on model of rats with acute exacerbation of chronic obstructive pulmonary disease. Results show that high dose, middle dose, or low dose of phlegmyheatclear can, during the acute exacerbation of chronic obstructive pulmonary disease, improve the lung function of the rats and the pathological damage of lung tissues of the rats in different degrees, and it is dose dependent. High dose, middle dose, or low dose of phlegmyheatclear can improve inflammatory reaction in different degrees. For the drug effects, the high dose and the middle dose of phlegmyheatclear are better than the low dose of phlegmyheatclear. Therefore, phlegmyheatclear can be used to prepare a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease.

The invention discloses an application of phlegmyheatclear in preparation of a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease. The present invention studies the effect of phlegmyheatclear on model of rats with acute exacerbation of chronic obstructive pulmonary disease. Results show that high dose, middle dose, or low dose of phlegmyheatclear can, during the acute exacerbation of chronic obstructive pulmonary disease, improve the lung function of the rats and the pathological damage of lung tissues of the rats in different degrees, and it is dose dependent. High dose, middle dose, or low dose of phlegmyheatclear can improve inflammatory reaction in different degrees. For the drug effects, the high dose and the middle dose of phlegmyheatclear are better than the low dose of phlegmyheatclear. Therefore, phlegmyheatclear can be used to prepare a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease.

Technologies relating to Chinese medicine composition used for treatment of protecting respiratory tract from viral infection by significantly increasing immunity of patients are disclosed. An example composition used for treatment of protecting respiratory tract from viral infection by significantly increasing immunity of a patient, includes: an Astragalus Root; a Ganoderma Spore; a Siberian Ginseng; an Underleaf Pearl; a Honeysuckle Flower; a Chinese Globe Flower; an Isatis Leaf; an Woad Root; a Patchouli; a Forsythia Fruit; an asiatic Pennywort; an Aged Tangerine Peel; a Giant Knotweed; a Reed Rhizome; an Unprepared Licorice Root; and a Fresh Ginger Rhizome.

Technologies relating to Chinese medicine composition used for treatment of protecting respiratory tract from viral infection by significantly increasing immunity of patients are disclosed. An example composition used for treatment of protecting respiratory tract from viral infection by significantly increasing immunity of a patient, includes: an Astragalus Root; a Ganoderma Spore; a Siberian Ginseng; an Underleaf Pearl; a Honeysuckle Flower; a Chinese Globe Flower; an Isatis Leaf; an Woad Root; a Patchouli; a Forsythia Fruit; an asiatic Pennywort; an Aged Tangerine Peel; a Giant Knotweed; a Reed Rhizome; an Unprepared Licorice Root; and a Fresh Ginger Rhizome.

Technologies relating to Chinese medicine composition used for treatment of protecting respiratory tract from viral infection by significantly increasing immunity of patients are disclosed. An example composition used for treatment of protecting respiratory tract from viral infection by significantly increasing immunity of a patient, includes: an Astragalus Root; a Ganoderma Spore; a Siberian Ginseng; an Underleaf Pearl; a Honeysuckle Flower; a Chinese Globe Flower; an Isatis Leaf; an Woad Root; a Patchouli; a Forsythia Fruit; an asiatic Pennywort; an Aged Tangerine Peel; a Giant Knotweed; a Reed Rhizome; an Unprepared Licorice Root; and a Fresh Ginger Rhizome.

Provided is a pharmaceutical composition including an Abeliophyllum distichum extract as an active ingredient for treating androgen receptor-related diseases. The Abeliophyllum distichum extract according to the presently claimed subject matter or isoquercetin has an inhibitory activity against the androgen receptor and an excellent therapeutic effect on benign prostatic hyperlasia animal models, thus this finding can apply widely to the industry for relevant therapeutic agents for androgen receptor-related diseases such as benign prostatic hyperplasia, androgen-dependent hair loss, dysuria, and prostate cancer.